Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 68

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 68
---
 exercisable thereunder shall be converted into shares of MIRA Common Stock pursuant to the Exchange Ratio.

Completion and Effectiveness of the Merger

The Merger will be completed as promptly as practicable after all of the conditions to Closing are satisfied or waived, including the approval of the stockholders of MIRA and of SKNY, unless earlier terminated in accordance with the terms of the Merger Agreement. For more information on termination rights, see the section titled “The Merger Agreement—Termination.” MIRA and SKNY cannot predict the exact timing of the Closing because it is subject to various conditions.

| 34 |

Conditions to the Merger

The completion of the Merger is subject to customary closing conditions, including but not limited to:

| ● | SKNY                                                                                                                                    
 shall have assets comprising any combination of cash and marketable securities with a total value of at least five million U.S. dollars 
 (US$5,000,000).                                                                                                                         |
| ● | There                                                                                                                                   
 shall be no temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Merger   
 issued by any court of competent jurisdiction or other governmental body of competent jurisdiction and that remains in effect, and      
 no law may have made the consummation of the Merger illegal.                                                                            |
| ● | Approval                                                                                                                                
 of the Merger by the stockholders of both MIRA and SKNY.                                                                                |
| ● | NASDAQ                                                                                                                                  
 shall not have objected to the consummation of the Merger and issuance of the Merger Consideration.                                     |
| ● | Receipt                                                                                                                                 
 of all necessary regulatory approvals.                                                                                                  |
| ● | No                                                                                                                                      
 material adverse changes occurring to the business or financial condition of either MIRA or SKNY.                                       |

SKNY Capitalization on Closing

As mentioned earlier, upon Closing, SKNY is to have assets comprising any combination of cash and marketable securities with a total value of at least five million U.S. dollars (US$5,000,000). It is expected that upon closing, SKNY will hold approximately $5 million worth of shares of Telomir Pharmaceuticals, Inc. (Nasdaq:TELO).

Approvals

The Board of Directors of SKNY has unanimously approved the Merger Agreement and recommends that shareholders of SKNY approve the Merger. Similarly, the Board of Directors of MIRA has approved the Merger and recommends that its shareholders vote “FOR” the issuance of shares in connection with the Merger.

Termination